| MDL | - |
|---|---|
| Molecular Weight | 421.46 |
| Molecular Formula | C24H24FN3O3 |
| SMILES | O=C1C2=CC(CC3=CC=C(N4C=CC=N4)C=C3)=C(C)C(F)=C2CN1[C@@H]5[C@H](CCOC5)O |
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC 50 of TAK-071 M1R agonist activities is 520 nM [1] .
EC50: 520 nM (M1R) [1]
TAK-071 increase hippocampal inositol monophosphate production through M1R activation and improved DB00747 -induced cognitive deficits in rats at 0.3 mg/kg [1] .
TAK-071 also induce diarrhea at 10 mg/kg in rats [1] .
Combining sub-effective doses of TAK-071 (3 mg/kg) with an acetylcholinesterase inhibitor significantly ameliorates DB00747-induced cognitive deficits in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02769065 | Takeda |
Alzheimer Disease|Healthy Volunteers
|
May 5, 2016 | Phase 1 |
| NCT04334317 | Takeda|Michael J. Fox Foundation for Parkinson´s Research |
Parkinson Disease|Healthy Participants
|
October 21, 2020 | Phase 2 |
| NCT02918266 | Takeda |
Healthy Volunteers
|
November 21, 2016 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 135 mg/mL ( 320.32 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3727 mL | 11.8635 mL | 23.7270 mL |
| 5 mM | 0.4745 mL | 2.3727 mL | 4.7454 mL |
| 10 mM | 0.2373 mL | 1.1864 mL | 2.3727 mL |